Explore

Trendline Trendline
Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA
Trendline Trendline
Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development
Trendline Trendline
Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes

Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes

Capricor and Replimune Face Uncertain FDA Advisory Committee Outcomes
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Trendline Trendline
Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update
Trendline Trendline
Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder

Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder

Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Study for Zodasiran Targeting Rare Cholesterol Disorder
Trendline Trendline
CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema

CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema

CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Trendline Trendline
Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies

Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies

Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Trendline Trendline
MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results

MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results

MapLight's Schizophrenia Drug Faces Challenges After Mixed Phase 2 Trial Results
Trendline Trendline
Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model